Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The HER2 receptor tyrosine kinase is a key target in HER2-positive breast cancer.
• A splice variant, d16HER2, lacking exon 16, is found in HER2-positive tumors and associated with trastuzumab resistance, but its role is unclear.

Purpose of the Study:

• To investigate the functional impact of d16HER2 on mammary tumorigenesis and response to trastuzumab.
• To elucidate the signaling pathways activated by d16HER2 and their clinical relevance.

Main Methods:

• Genetic studies in transgenic mice to assess d16HER2 function.
• Comparative analysis of signaling pathways activated by d16HER2 and wild-type HER2.
• Clinical correlation analysis of d16HER2 and pSRC in patient tumor samples.

Main Results:

• d16HER2 expression accelerates mammary tumor development in mice.
• d16HER2 signaling is optimally functional via SRC activation (pSRC).
• Clinical data show a correlation between d16HER2, pSRC, and improved trastuzumab efficacy.

Conclusions:

• The d16HER2 splice variant promotes tumorigenesis and enhances trastuzumab response.
• The d16HER2-pSRC signaling axis is a predictive biomarker for trastuzumab treatment.
• d16HER2 expression indicates a lower risk of relapse after trastuzumab therapy.